Pub Date : 2019-10-23DOI: 10.33552/appr.2019.01.000535
A. Kaushik
{"title":"Antiurolithiatic Activity of the Leaf Extracts of Maerua Angolensis","authors":"A. Kaushik","doi":"10.33552/appr.2019.01.000535","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000535","url":null,"abstract":"","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87695729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-23DOI: 10.33552/appr.2019.02.000535
A. Kaushik
{"title":"Antiurolithiatic Activity of the Leaf Extracts of Maerua Angolensis","authors":"A. Kaushik","doi":"10.33552/appr.2019.02.000535","DOIUrl":"https://doi.org/10.33552/appr.2019.02.000535","url":null,"abstract":"","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79297254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-01DOI: 10.33552/appr.2019.01.000534
J. Rozich
Mounting evidence has suggested that the cardiac extracellular matrix (ECM) has a nuanced but determinative role in myocardial remodeling in response to pathological insult and subsequent recovery [1-3]. These alterations in the structure and actual composition of ECM may actually reflect many of the welldescribed phenotypic cardiac properties typical of common diseases states including diabetes, hypertension, obesity and ischemia. Current thought is that dysregulatory influences result in a maladaptive remodeling process that begins an inevitable progression to irreversible and often untimely cardiac failure [1,2]. This potentially injurious perturbation in the dysfunctional ECM response is complex involving profibrotic collagen synthesis and post-translational modification including increased crosslinking and reduced degradation [1,4]. The result is a stiffening noncompliant and impaired myocardium that underpins observed clinical changes causing the heart failure syndrome. Sampling changing serum levels of distinct proteins or molecular fragments are now being used to assess collagen turnover. This includes using the N-terminal propeptide of procollagen type III and C-terminal propeptide of procollagen type I considered directly correlative to histologically proven fibrosis [1,5]. Other biomarkers have been proposed to be associated with pathology involving collagen metabolism, (tissue inhibitor of metalloproteinases-1 (TIMP-1), matrix metalloproteinase [MMP]-2, MMP-9, galectin-3 [Gal-3], etc) but are not yet validated as directly representative of histologically confirmed fibrosis [1,6].
{"title":"The Collagen Challenge: Preventing Myocardial Fibrosis Is the Hype Reflective of the Potential?","authors":"J. Rozich","doi":"10.33552/appr.2019.01.000534","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000534","url":null,"abstract":"Mounting evidence has suggested that the cardiac extracellular matrix (ECM) has a nuanced but determinative role in myocardial remodeling in response to pathological insult and subsequent recovery [1-3]. These alterations in the structure and actual composition of ECM may actually reflect many of the welldescribed phenotypic cardiac properties typical of common diseases states including diabetes, hypertension, obesity and ischemia. Current thought is that dysregulatory influences result in a maladaptive remodeling process that begins an inevitable progression to irreversible and often untimely cardiac failure [1,2]. This potentially injurious perturbation in the dysfunctional ECM response is complex involving profibrotic collagen synthesis and post-translational modification including increased crosslinking and reduced degradation [1,4]. The result is a stiffening noncompliant and impaired myocardium that underpins observed clinical changes causing the heart failure syndrome. Sampling changing serum levels of distinct proteins or molecular fragments are now being used to assess collagen turnover. This includes using the N-terminal propeptide of procollagen type III and C-terminal propeptide of procollagen type I considered directly correlative to histologically proven fibrosis [1,5]. Other biomarkers have been proposed to be associated with pathology involving collagen metabolism, (tissue inhibitor of metalloproteinases-1 (TIMP-1), matrix metalloproteinase [MMP]-2, MMP-9, galectin-3 [Gal-3], etc) but are not yet validated as directly representative of histologically confirmed fibrosis [1,6].","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75535982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-26DOI: 10.33552/appr.2019.01.000533
E. Nunes
Schizophrenia follows as one of the most challenge mental disorders, despite the highly available pharmacological treatment options, currently represented mainly by antipsychotic medications [1,2]. Most of these antipsychotic medications have in common some level of antagonism of dopamine type 2 receptors (D2) and also blockade of 5HT2A serotonin receptors is present in some of these compounds [3,4]. Even with the different types of currently available antipsychotics, all of them as stated earlier, have in common some blockade of D2 receptors. This pharmacodynamics effect is in accordance to the main theory that tries to explain the physiopathology of schizophrenia, the dopaminergic theory (CARLSSON AND LINDQVIST, 1963). Albeit reasonable improvement can be achieved with the use of antipsychotic to treat schizophrenia symptoms, especially when we consider the positive symptoms (hallucinations and delusions), almost one third of all patients is completely refractory to pharmacological approaches [1,5]. Therefore, the need for new drugs that target other neurotransmission systems other than the dopamine transmission is urgent [6] and the neuroactive steroids, like pregnenolone glutamate has attracted great attention ISSN: 2641-2020 DOI: 10.33552/APPR.2019.02.000533
精神分裂症是最具挑战性的精神障碍之一，尽管有高度可用的药物治疗选择，目前主要是抗精神病药物[1,2]。大多数抗精神病药物都有一定程度的多巴胺2型受体(D2)拮抗作用，其中一些化合物也存在5HT2A血清素受体的阻断作用[3,4]。即使是目前可用的不同类型的抗精神病药物，如前所述，它们都有一些共同的D2受体阻断。这种药效学效应符合试图解释精神分裂症生理病理的主要理论，即多巴胺能理论(CARLSSON AND LINDQVIST, 1963)。尽管使用抗精神病药物治疗精神分裂症症状可以实现合理的改善，特别是当我们考虑到阳性症状(幻觉和妄想)时，几乎三分之一的患者对药物治疗完全难治[1,5]。因此，迫切需要针对多巴胺传递以外的其他神经传递系统的新药[6]，孕烯醇酮谷氨酸等神经活性类固醇引起了人们的极大关注。ISSN: 2641-2020 DOI: 10.33552/APPR.2019.02.000533
{"title":"Effects of Antipsychotic Drugs on Neuroactive Steroids Brain and Plasma Levels in Humans and Animals: A Systematic Review of the Literature","authors":"E. Nunes","doi":"10.33552/appr.2019.01.000533","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000533","url":null,"abstract":"Schizophrenia follows as one of the most challenge mental disorders, despite the highly available pharmacological treatment options, currently represented mainly by antipsychotic medications [1,2]. Most of these antipsychotic medications have in common some level of antagonism of dopamine type 2 receptors (D2) and also blockade of 5HT2A serotonin receptors is present in some of these compounds [3,4]. Even with the different types of currently available antipsychotics, all of them as stated earlier, have in common some blockade of D2 receptors. This pharmacodynamics effect is in accordance to the main theory that tries to explain the physiopathology of schizophrenia, the dopaminergic theory (CARLSSON AND LINDQVIST, 1963). Albeit reasonable improvement can be achieved with the use of antipsychotic to treat schizophrenia symptoms, especially when we consider the positive symptoms (hallucinations and delusions), almost one third of all patients is completely refractory to pharmacological approaches [1,5]. Therefore, the need for new drugs that target other neurotransmission systems other than the dopamine transmission is urgent [6] and the neuroactive steroids, like pregnenolone glutamate has attracted great attention ISSN: 2641-2020 DOI: 10.33552/APPR.2019.02.000533","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87742850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-25DOI: 10.33552/appr.2019.01.000532
Bushra Khalid
Influenza is caused by Influenza virus which has many types A, B, C and D. Each type is divided into subtypes like Influenza A (H1N1 and H3N2) are most common. Its symptoms have resemblance with cold but if it is not treated properly then many nearby healthy individual also affected by flu. Vaccination is best way for prevention but some people prefers medication while other prefer home remedies for flu treatment. Heart is muscular organ which is responsible for blood pumping moreover a healthy pulse rate declare that heart is at right state. Abnormal pulse rate is associated with many other illnesses. To measure the pulse rate, hold the hand as its palm side up and by placing the two fingers on wrist feel pulse rate and count it for one minute by using stopwatch. Finally, here is significant relation is observed for flu treatment with pulse rate.
{"title":"Relation of Pulse Rate with Flu Medication Treatment","authors":"Bushra Khalid","doi":"10.33552/appr.2019.01.000532","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000532","url":null,"abstract":"Influenza is caused by Influenza virus which has many types A, B, C and D. Each type is divided into subtypes like Influenza A (H1N1 and H3N2) are most common. Its symptoms have resemblance with cold but if it is not treated properly then many nearby healthy individual also affected by flu. Vaccination is best way for prevention but some people prefers medication while other prefer home remedies for flu treatment. Heart is muscular organ which is responsible for blood pumping moreover a healthy pulse rate declare that heart is at right state. Abnormal pulse rate is associated with many other illnesses. To measure the pulse rate, hold the hand as its palm side up and by placing the two fingers on wrist feel pulse rate and count it for one minute by using stopwatch. Finally, here is significant relation is observed for flu treatment with pulse rate.","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88079435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-18DOI: 10.33552/appr.2019.01.000531
Mohammed Rahmatullah Dean
Plants produce a bewildering variety of phytochemicals, otherwise known as secondary metabolites. Secondary metabolites are compounds, which are not necessary for a plant cell to live but are necessary for a plant to survive biotic or abiotic stresses [1]. Secondary metabolites can produce pharmacological responses when introduced into humans, which in turn can be toxic or serve therapeutic purposes. A number of such secondary metabolites have been isolated and have found uses in medicine like aconitine, L-hyoscyamine, camptothecin, tetrahydrocannabinol, and tubocurarine, to name only a few [2]. Although the existence of secondary metabolites were possibly not known or understood by ancient hominids, plants have always played a role in the treatment of diseases from the beginning of humankind. Medicinal plant material has been found in a 60, 000 year old Neanderthal grave in Iraq [3]. Early Asian and Egyptian texts (since the discovery of writing and writing materials) mention medicinal plants and their uses [4]. Use of plants as medicines since time immemorial gradually led to the establishment of distinct forms of traditional medicinal practices like the Ayurveda in India, Unani in Greece, Kampo in Japan, and other systems throughout the world [5]. Besides these ‘ritualized’ forms of traditional medicinal systems, there also exists folk medicine (FM), tribal medicine (TM, same as FM but practiced by tribal people instead of the mainstream population), and home remedies. Allopathic medicine has borrowed heavily from traditional medicinal practices and more than a hundred allopathic drugs are plant-derived [6]. It has been said that approximately 7080% of primary health care throughout the world is based on plant materials [7].
{"title":"Mikania Cordata (Burm.F.) B.L. Rob. – A Bangladesh Folk Medicinal Plant for Gastric Disorders","authors":"Mohammed Rahmatullah Dean","doi":"10.33552/appr.2019.01.000531","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000531","url":null,"abstract":"Plants produce a bewildering variety of phytochemicals, otherwise known as secondary metabolites. Secondary metabolites are compounds, which are not necessary for a plant cell to live but are necessary for a plant to survive biotic or abiotic stresses [1]. Secondary metabolites can produce pharmacological responses when introduced into humans, which in turn can be toxic or serve therapeutic purposes. A number of such secondary metabolites have been isolated and have found uses in medicine like aconitine, L-hyoscyamine, camptothecin, tetrahydrocannabinol, and tubocurarine, to name only a few [2]. Although the existence of secondary metabolites were possibly not known or understood by ancient hominids, plants have always played a role in the treatment of diseases from the beginning of humankind. Medicinal plant material has been found in a 60, 000 year old Neanderthal grave in Iraq [3]. Early Asian and Egyptian texts (since the discovery of writing and writing materials) mention medicinal plants and their uses [4]. Use of plants as medicines since time immemorial gradually led to the establishment of distinct forms of traditional medicinal practices like the Ayurveda in India, Unani in Greece, Kampo in Japan, and other systems throughout the world [5]. Besides these ‘ritualized’ forms of traditional medicinal systems, there also exists folk medicine (FM), tribal medicine (TM, same as FM but practiced by tribal people instead of the mainstream population), and home remedies. Allopathic medicine has borrowed heavily from traditional medicinal practices and more than a hundred allopathic drugs are plant-derived [6]. It has been said that approximately 7080% of primary health care throughout the world is based on plant materials [7].","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75446417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-13DOI: 10.33552/appr.2019.01.000530
Gretchen M. Kipp, L. Biondi, D. Kannabhiran
The survival benefit of kidney transplantation for patients with end-stage renal disease (ESRD) is well established. However, the demand for kidney donor organs greatly exceeds the current supply. The use of hepatitis C infected donors could increase the number of kidneys available for transplantation. The use of highly effective second-generation direct acting antivirals (DAAs) has been recently studied for the prevention of chronic hepatitis C virus (HCV) infection in kidney transplant recipients who are HCV negative and receive HCV infected kidney allografts. Small, open-label trials have demonstrated the feasibility of using DAAs as either preand post-exposure prophylaxis or as treatment after detection of HCV transmission. Short term outcomes illustrate 100% prevention of chronic HCV infection with renal function and allograft survival that are comparable to recipients of non-HCV infected kidney donors. Long-term allograft and patient outcomes are required to determine whether the use of HCV infected organs should be considered for all patients with ESRD waiting for kidney transplant. The survival benefit of kidney transplantation for patients with end-stage renal disease (ESRD) is well established [1,2]. However, the demand for kidney donor organs greatly exceeds the current supply which encourages organ procurement organizations and transplant centers to look for innovative strategies to increase the donor pool. Recently, the opioid crisis has increased the number of overdose deaths exponentially [3]. Additionally, the number of hepatitis C virus (HCV) seropositive donors increased from 452 organs per year to 1506 per year between the years of 2000 and 2016 but only 57% of the HCV seropositive kidneys were transplanted in 2016 [4]. The use of hepatitis C infected donors could increase the number of kidneys available for transplantation but this strategy has historically been avoided because of risk of HCV transmission as well as inadequate treatment response and risk of rejection with interferon-based regimens. The advent of highly effective secondgeneration direct acting antivirals (DAAs) has increased viral cure of patients with chronic HCV infection to more than 96% [5-7]. Ongoing research is investigating whether DAAs can be prescribed post-transplant to HCV negative recipients receiving HCV infected donors to increase the donor pool.
{"title":"Expanding the Kidney Donor Pool through Use of Hepatitis C-Infected Donors: is it Time to Dive in?","authors":"Gretchen M. Kipp, L. Biondi, D. Kannabhiran","doi":"10.33552/appr.2019.01.000530","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000530","url":null,"abstract":"The survival benefit of kidney transplantation for patients with end-stage renal disease (ESRD) is well established. However, the demand for kidney donor organs greatly exceeds the current supply. The use of hepatitis C infected donors could increase the number of kidneys available for transplantation. The use of highly effective second-generation direct acting antivirals (DAAs) has been recently studied for the prevention of chronic hepatitis C virus (HCV) infection in kidney transplant recipients who are HCV negative and receive HCV infected kidney allografts. Small, open-label trials have demonstrated the feasibility of using DAAs as either preand post-exposure prophylaxis or as treatment after detection of HCV transmission. Short term outcomes illustrate 100% prevention of chronic HCV infection with renal function and allograft survival that are comparable to recipients of non-HCV infected kidney donors. Long-term allograft and patient outcomes are required to determine whether the use of HCV infected organs should be considered for all patients with ESRD waiting for kidney transplant. The survival benefit of kidney transplantation for patients with end-stage renal disease (ESRD) is well established [1,2]. However, the demand for kidney donor organs greatly exceeds the current supply which encourages organ procurement organizations and transplant centers to look for innovative strategies to increase the donor pool. Recently, the opioid crisis has increased the number of overdose deaths exponentially [3]. Additionally, the number of hepatitis C virus (HCV) seropositive donors increased from 452 organs per year to 1506 per year between the years of 2000 and 2016 but only 57% of the HCV seropositive kidneys were transplanted in 2016 [4]. The use of hepatitis C infected donors could increase the number of kidneys available for transplantation but this strategy has historically been avoided because of risk of HCV transmission as well as inadequate treatment response and risk of rejection with interferon-based regimens. The advent of highly effective secondgeneration direct acting antivirals (DAAs) has increased viral cure of patients with chronic HCV infection to more than 96% [5-7]. Ongoing research is investigating whether DAAs can be prescribed post-transplant to HCV negative recipients receiving HCV infected donors to increase the donor pool.","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74791964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-09DOI: 10.33552/appr.2019.01.000529
Mohammed Rahmatullah Dean
Folk medicine (FM) is practiced by part-time or full-time folk medicinal practitioners (FMPs) in Bangladesh, utilizing for the most part plant-based remedies as their modus operandi for treatment of practically all ailments suffered by the Bangladesh people. FM is not unique to Bangladesh; it is present in practically every country of the world under different names or guises like home remedies, herbal remedies, etc. With time, FM can even take on a more formal form in which cases they are known as Ayurveda and Siddha (in India), Unani (in Greece) or Kampo (in Japan). People of Thailand are said to use herbal remedies since the Sukothai period (12381377) [1]. However, the use of plants as medicines dates back to much earlier times. Radiocarbon dating shows that plants were cultivated in ancient Babylon (present Iraq) more than 60,000 years ago [2]. It is possibly safe to say that human beings have suffered from ailments since their very advent and have tried to cure such ailments possibly from the earliest human ancestors about 6-7 million years ago – the Australopithecines [3]. It is to be taken into account that the great apes and other animal species instinctively partake of some plants for medicinal purposes [4], and the earliest hominids could have easily caught onto this ‘cure’ system.
{"title":"Do Folk Medicinal Practices of Bangladesh Have any Scientific Value? an Appraisal of Phytotherapeutic Practices of a Rural Folk Medicinal Practitioner","authors":"Mohammed Rahmatullah Dean","doi":"10.33552/appr.2019.01.000529","DOIUrl":"https://doi.org/10.33552/appr.2019.01.000529","url":null,"abstract":"Folk medicine (FM) is practiced by part-time or full-time folk medicinal practitioners (FMPs) in Bangladesh, utilizing for the most part plant-based remedies as their modus operandi for treatment of practically all ailments suffered by the Bangladesh people. FM is not unique to Bangladesh; it is present in practically every country of the world under different names or guises like home remedies, herbal remedies, etc. With time, FM can even take on a more formal form in which cases they are known as Ayurveda and Siddha (in India), Unani (in Greece) or Kampo (in Japan). People of Thailand are said to use herbal remedies since the Sukothai period (12381377) [1]. However, the use of plants as medicines dates back to much earlier times. Radiocarbon dating shows that plants were cultivated in ancient Babylon (present Iraq) more than 60,000 years ago [2]. It is possibly safe to say that human beings have suffered from ailments since their very advent and have tried to cure such ailments possibly from the earliest human ancestors about 6-7 million years ago – the Australopithecines [3]. It is to be taken into account that the great apes and other animal species instinctively partake of some plants for medicinal purposes [4], and the earliest hominids could have easily caught onto this ‘cure’ system.","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"96 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73288995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-09DOI: 10.33552/appr.2019.02.000529
M. Rahmatullah
{"title":"Do Folk Medicinal Practices of Bangladesh Have any Scientific Value? an Appraisal of Phytotherapeutic Practices of a Rural Folk Medicinal Practitioner","authors":"M. Rahmatullah","doi":"10.33552/appr.2019.02.000529","DOIUrl":"https://doi.org/10.33552/appr.2019.02.000529","url":null,"abstract":"","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83000918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：